Trials / Completed
CompletedNCT01292161
Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
Study of Silymarin for Improving Hepatitis C
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Isfahan University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.
Detailed description
Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Silymarin | Tab 210 mg, 630 mg, daily, six months. |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2011-02-09
- Last updated
- 2011-02-09
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT01292161. Inclusion in this directory is not an endorsement.